Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

ClinicalTrials.gov ID: NCT06039449

Public ClinicalTrials.gov record NCT06039449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 1:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Evaluate the Efficacy and Safety of VYD222 for Prevention of COVID-19 (CANOPY)

Study identification

NCT ID
NCT06039449
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Invivyd, Inc.
Industry
Enrollment
790 participants

Conditions and interventions

Interventions

  • VYD222 (pemivibart) Drug
  • Normal saline Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 7, 2023
Primary completion
Nov 18, 2024
Completion
Nov 18, 2024
Last update posted
Dec 8, 2024

2023 – 2024

United States locations

U.S. sites
18
U.S. states
9
U.S. cities
18
Facility City State ZIP Site status
INVIVYD Investigative Site Fullerton California 92835
INVIVYD Investigative Site Long Beach California 90806
INVIVYD Investigative Site Rolling Hills Estates California 90274
INVIVYD Investigative Site San Diego California 92103
INVIVYD Investigative Site Clearwater Florida 33756
INVIVYD Investigative Site Miami Florida 33186
INVIVYD Investigative Site St. Petersburg Florida 33705
INVIVYD Investigative Site Atlanta Georgia 30328
INVIVYD Investigative Site Hinesville Georgia 31313
INVIVYD Investigative Site Oak Brook Illinois 60523
INVIVYD Investigative Site Silver Spring Maryland 20904
INVIVYD Investigative Site Burlington Massachusetts 01803
INVIVYD Investigative Site Morrisville North Carolina 27560
INVIVYD Investigative Site Salisbury North Carolina 28144
INVIVYD Investigative Site Edmond Oklahoma 73013
INVIVYD Investigative Site Yukon Oklahoma 73099
INVIVYD Investigative Site Beaumont Texas 77706
INVIVYD Investigative Site Dallas Texas 75230

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06039449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 8, 2024 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06039449 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →